Product, Cancer research, Complex disease genomics

Illumina Announces New NovaSeq Flow Cell

Extended kit configurations provide increased flexibility and utility for high throughput sequencing

Illumina Announces New NovaSeq Flow Cell
17 June 2018

NovaSeq™ has enabled researchers to employ novel experimental approaches to explore genetic variation associated with health and disease. The throughput and compelling economics of the new platform are enabling broader and deeper studies, many of which weren’t practical even a few years ago. Illumina continues to invest in the new system with the goal of enabling an even greater range of sequencing methods and applications. Today, Illumina announced two extensions to its core consumables portfolio for the NovaSeq 6000 Sequencing System.

  • The S4 200 Cycle Kit will enable customers to extend their research across more applications including single-cell and exome sequencing.
  • The S Prime (SP) Flow Cell is designed for smaller run sizes and/or applications that require lower sequencing output. The new kit will be available in 100 and 300 cycle configurations, with an output of 250G (300 cycle). It is ideally suited for Illumina customers transitioning from HiSeq™, and new customers introducing high throughput sequencing in their labs.

“We actively seek customer feedback regarding how we can further extend and enhance the capabilities of NovaSeq. The new SP Flow Cell and S4 Cycle Kit configuration are a direct result of their input,” shared Joel Fellis, Director, Product Marketing, Sequencing Systems at Illumina. “The new products offer customers additional flexibility to leverage a single sequencing platform to address a wide range of experiment types and applications.”

The NovaSeq 6000 Sequencing System now offers four different flow cells: SP, S1, S2 and S4. Users can mix and match flow cells and kit configurations to most efficiently execute their experimental plan. To learn more about the advantages of the NovaSeq, the S4 200 Cycle Kit, and the SP Flow Cell, please visit www.illumina.com/NovaSeq. These products are expected to be available in Q4 2018.

For Research Use Only.  Not for use in diagnostic procedures.

Recent Articles

Liquid-based CGP is critical for matching cancer patients to therapies
Liquid-based CGP is critical for matching cancer patients to therapies
Operating a speedy, high-tech NGS lab in remote Australia
Operating a speedy, high-tech NGS lab in remote Australia
How researchers are moving multiomics forward with Illumina technology
Video: How researchers are moving multiomics forward with Illumina technology